IL1B and inflammatory bowel disease: Our observation that synbiotic treatment reduces these cytokines aligns with B. coagulans-mediated immunomodulation reported in prior studies, specifically, B. coagulans Unique IS-2 has been shown to decrease TNF-α and IL-1β levels in inflammatory bowel disease patients, likely through immunomodulatory pathways [26,27,49].